Why the study?
Does combination therapy improve adherence to treatment in patients with hypertension?
Does combination therapy improve adherence to treatment in patients with hypertension?
Combination therapies for hypertension have the potential to increase patient adherence by offering a favorable tolerability profile and once-daily dosing.
Answers are grounded in this paper and cite their sources.
May support once-daily combinations to improve adherence; leaves open prospective RCTs on outcomes.
Patient adherence to antihypertensive medication is vital to ensure the successful treatment of hypertension. Low levels of adherence to and persistence with prescribed therapy are major factors leading to the current poor rates of blood pressure control among patients with hypertension. There are many reasons for nonadherence to therapy including patient-, physician-, and therapy-related factors. Poor tolerability has a detrimental effect on adherence, therefore reducing the apparent effectiveness of agents with dose-dependent side effects. Various effective combination therapies are recommended by current guidelines, eg, beta-blocker plus calcium channel blocker (CCB), angiotensin receptor blocker (ARB) plus thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitor plus thiazide diuretic, CCB plus thiazide diuretic, ACE inhibitor plus CCB, and ARB plus CCB, and these have the potential to increase adherence to therapy by combining a favorable tolerability profile with once-daily dosing.
No takes yet. Share an insight, caveat, or question.
Serap Erdine (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: